Soren Tulstrup is President & CEO of Hansa Biopharma AB, an innovative and rapidly growing biopharmaceutical company listed on Nasdaq Nordic. He also serves as board director and advisor to a number of private and public life science companies in Europe and North America. Soren Tulstrup has more than 30 years of senior level experience within the global life science industry as CEO/General Manager/Global Franchise Head/Region Head and board director at leading and fast growing companies in Europe, the US and Emerging Markets. He has a strong track record of building, transforming and scaling biotech and specialty pharma companies through establishment of high-performance management teams, organizational restructuring, capital attraction, acceleration of pipeline projects, successful product launches, and business development and M&A activities.As CEO of Swiss specialty pharma company Vifor Pharma, Soren Tulstrup initiated and led a major turn-around effort that resulted in significant acceleration of sales growth and a substantial operating margin improvement and led to the spin-out of Vifor Pharma from the mother group Galenica. Driven by the performance of Vifor Pharma, Galenica became the best performing share (+98 %) within the Swiss Performance Index, increasing the company’s market cap by approx. CHF 5 billion. Based on this performance and a range of other objective criteria, Soren Tulstrup made the #2 spot on local newspaper Handelzeitung’s list of Switzerland’s most value-adding CEOs in the category Large Companies.Previously, as CEO of successful biotech company Santaris Pharma, Soren Tulstrup initiated a refocusing of the company’s drug development efforts, established US operations in San Diego, and led business development efforts that resulted in 4 major partner deals within 3 years with a total deal value of almost USD 2 billion in upfront and potential milestone payments, enabling the company to take 3 new drug candidates into clinical development without raising new capital. Santaris Pharma was listed as a Fierce 15 Biotech Company, won the Red Herring Award and was nominated for the SCRIP Award in the category Best Biotech Company before eventually being acquired by Roche and providing the investors with an attractive return.Soren Tulstrup holds an MSc. in Economics and Business Administration from Copenhagen Business School and Kellogg Graduate School of Management, Northwestern University. He is also a graduate of the Royal Danish Army Combat School and has served as an armored infantry officer in the Royal Danish Army.